证券代码：300260 证券简称：新莱应材 公告编号：2024-036 昆山新莱洁净应用材料股份有限公司 关于变更审计机构暨聘任2024年度审计机构的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、前任会计师事务所：大华会计师事务所（特殊普通合伙）（以下简称"大华"）。 2、拟聘任会计师事务所：容诚会计师事务所（特殊普通合伙）（以下简 称"容诚"）。 3、拟变更会计师事务所的原因：鉴于昆山新莱洁净应用材料股份有限公 司（以下简称"公司"）聘任的 2023 年度审计机构大华会计师事务所（特殊普通 合伙）收到中国证监会江苏监管局下发的《行政处罚决定书》（【2024】1 号）， 被暂停从事证券服务 6 个月，基于谨慎性原则，结合经营管理需要，公司拟变 更会计师事务所。公司已就该事项与大华进行了沟通说明，其已明确知悉本次变 更事项并确认无异议。经公司履行选聘程序后，拟聘任容诚会计师事务所（特 殊普通合伙）为公司 2024 年度财务报告审计和内部控制审计机构。 4、公司董事会及董事会审计委员会对本次变更会计师事务所事项无异议。 5、本次变更会计师事务所符 ...

根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等相关法律法规、规范性文件及《公司章程》《独立董事工作细则》的有关规定， 昆山新莱洁净应用材料股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日 召开了第六届董事会 2024 年第二次独立董事专门会议。基于完全独立、认真、 审慎的立场，本着对公司及全体股东负责的态度，在认真阅读和审核相关材料的 基础上，对公司第六届董事会第五次会议所审议案的相关情况进行了核查，并发 表审查意见如下： 一、关于公司变更审计机构暨聘任 2024 年度审计机构的审查意见 经核查，我们认为：容诚会计师事务所（特殊普通合伙）具备独立性、审计 的专业能力和资质以及投资者保护能力，能够满足公司审计要求，聘任其是基于 公司业务发展需要，有利于保证审计工作的连续性和稳定性，不存在损害公司及 其他股东利益、尤其是中小股东利益的情况。我们同意董事会聘任容诚会计师事 务所（特殊普通合伙）为公司 2024 年度财务报告审计和内部控制审计机构，并 同意将该事项提交董事会审议。该事项尚需提交股东 ...

本公司及监事会全体成员保证本公告内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 证券代码：300260 证券简称：新莱应材 公告编号：2024-034 昆山新莱洁净应用材料股份有限公司 第六届监事会第五次会议决议公告 昆山新莱洁净应用材料股份有限公司（以下简称"公司"）第六届监事会第五 次会议于2024年10月23日以现场方式召开，会议通知已于2024年10月14日以电子 邮件方式向全体监事发出。本次监事会会议应出席监事3人，实际出席监事3人。 会议由监事会主席郭兴云先生主持，此次会议的召开符合《公司法》等相关法律 法规以及《公司章程》等制度的规定，合法有效。 二、监事会会议审议情况 （一）审议通过了《关于2024年第三季度报告的议案》 经审议，监事会认为：董事会编制的《2024年第三季度报告》的程序符合法 律、行政法规和中国证监会的规定，报告内容公允地反映了公司2024年第三季度 的经营状况和成果，报告所披露信息真实、准确、完整，不存在虚假记载、误导 性陈述或重大遗漏。具体内容详见于同日在中国证监会指定的创业板信息披露网 站（www.cninfo.com.cn）上的披 ...

Financial Performance - The company's revenue for Q3 2024 reached ¥743,323,623.28, representing a year-on-year increase of 4.92%[3] - The net profit attributable to shareholders for Q3 2024 was ¥51,474,782.48, showing a decrease of 6.74% compared to the same period last year[3] - Basic earnings per share for Q3 2024 were ¥0.1411, a slight decrease of 0.18% year-on-year[3] - Total operating revenue for Q3 2024 reached CNY 2,161,486,987.46, an increase of 9.3% compared to CNY 1,976,583,377.34 in Q3 2023[12] - Net profit attributable to shareholders of the parent company was CNY 198,031,501.01, up 17.7% from CNY 168,346,572.68 in the same period last year[13] - Operating profit for the period was CNY 224,524,482.94, representing a growth of 14.8% compared to CNY 195,559,586.70 in Q3 2023[12] - The total comprehensive income for the period was CNY 193,316,276.31, compared to CNY 173,601,479.86 in the same quarter last year, reflecting an increase of 11.3%[13] Cash Flow and Liquidity - The operating cash flow net amount for the year-to-date period was ¥207,721,451.74, reflecting an increase of 84.15%[6] - The net cash flow from operating activities for Q3 2024 was CNY 207,721,451.74, an increase from CNY 112,797,194.62 in Q3 2023, representing an 84.1% growth[15] - Cash flow from operating activities amounted to CNY 2,424,745,669.89, compared to CNY 2,205,763,711.64 in the previous year, reflecting a growth of 9.9%[14] - The cash and cash equivalents increased significantly to CNY 457,919,881.66 from CNY 295,991,638.48, marking a growth of approximately 54.5%[10] - The cash and cash equivalents at the end of Q3 2024 totaled CNY 255,576,619.76, compared to CNY 217,586,542.11 at the end of Q3 2023, marking a 17.4% increase[15] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥4,811,319,893.64, an increase of 10.60% from the end of the previous year[3] - Current assets rose to CNY 3,087,775,163.02, compared to CNY 2,743,009,293.81 at the start of the year, indicating an increase of about 12.6%[10] - Total liabilities increased to CNY 2,874,433,858.47 from CNY 2,562,878,150.66, representing a rise of approximately 12.1%[11] - The company's equity attributable to shareholders was ¥1,928,862,524.44, up 8.38% compared to the previous year-end[3] - The company's equity attributable to shareholders increased to CNY 1,928,862,524.44 from CNY 1,779,788,600.99, reflecting a growth of approximately 8.4%[11] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,626, with the top 10 shareholders holding a combined 56.06% of shares[7] - The largest shareholder, Li Shuibo, holds 25.06% of shares, amounting to 102,200,850 shares[7] - The company’s major shareholders include Shen Anyun (16.71%), Li Baihua (6.90%), and Li Baiyuan (6.88%)[7] - The company has a shareholding structure where the actual controllers are Li Shuibo and Shen Anyun, who are spouses[7] Share Repurchase Plan - The company plans to repurchase shares using its own funds, with a total amount not less than RMB 50 million and not exceeding RMB 100 million, at a price not exceeding RMB 43 per share[9] - As of August 26, 2024, the company has repurchased a total of 2,013,571 shares, accounting for 0.4938% of the total share capital, with a total transaction amount of RMB 53,562,102.05[9] - The company has implemented a share repurchase plan that complies with relevant laws and regulations[9] - The maximum purchase price during the repurchase was RMB 33.00 per share, and the minimum was RMB 21.07 per share[9] Research and Development - Research and development expenses were CNY 78,107,865.20, slightly up from CNY 75,792,459.75 in Q3 2023, indicating continued investment in innovation[12] Tax and Employee Compensation - The company reported a decrease in tax expenses to CNY 8,799,745.76 from CNY 9,609,621.07 in the previous year, a reduction of 8.4%[12] - The company reported a decrease in employee compensation payable to CNY 39,696,039.10 from CNY 55,076,050.13, a reduction of approximately 28%[11] - The company paid CNY 301,387,902.13 in employee-related cash outflows, compared to CNY 172,187,026.88 in the previous year, representing a significant increase of 75.8%[15]

Profit Performance - Net profit attributable to shareholders of the listed company is expected to be between 180 million yuan and 210 million yuan, an increase of 6.92% to 24.74% compared to the same period last year[2] - Net profit after deducting non-recurring gains and losses is expected to be between 166 million yuan and 196 million yuan, an increase of 1.74% to 20.12% compared to the same period last year[2] - Net profit attributable to shareholders in Q3 2024 is expected to be between 39.52 million yuan and 69.52 million yuan, a change of -31.46% to 20.58% compared to the same period last year[2] - Net profit after deducting non-recurring gains and losses in Q3 2024 is expected to be between 33.87 million yuan and 63.87 million yuan, a change of -38.64% to 15.71% compared to the same period last year[2] - The increase in net profit is mainly due to the recovery in demand in the domestic semiconductor industry and improved order intake, while maintaining market share in the food industry despite reduced downstream customer demand[4] Industry and Investment Focus - The company has significantly increased its investment in the semiconductor industry, leading to higher fixed asset depreciation and a decline in gross margin compared to the same period last year[4] - R&D expenses have increased significantly compared to the same period last year, particularly due to deeper involvement in the semiconductor industry[4] Non-Recurring Items - Non-recurring gains and losses amounted to approximately 14 million yuan during the reporting period[4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected increase in stock price relative to the market benchmark index by over 20% in the next six months [15]. Core Insights - The company, Xinlai Yingcai, reported a revenue of 1.418 billion yuan for the first half of 2024, representing a year-on-year growth of 11.83%, with a net profit of 140 million yuan, up 26.91% [1]. - In Q2 2024, the company achieved a revenue of 729 million yuan, a 15.88% increase year-on-year, and a net profit of 72 million yuan, growing by 26.49% [1]. - The gross margin for H1 2024 was 25.57%, an increase of 0.74 percentage points year-on-year, while the net margin was 9.89%, up 1.18 percentage points [1]. - The company is focusing on R&D investments, particularly in the semiconductor sector, which is expected to drive future growth [1]. Business Segment Summary - **Semiconductor Segment**: Revenue reached 447 million yuan, a significant increase of 48.0% year-on-year, although the gross margin decreased by 1.4 percentage points to 28.34% due to increased depreciation from higher investments [1]. - **Food Segment**: Revenue was 803 million yuan, a slight increase of 0.1% year-on-year, with a gross margin of 22.7%, up 3.4 percentage points. The company is enhancing its market share in domestic clients despite reduced demand from major dairy clients [1]. - **Pharmaceutical Segment**: Revenue was 169 million yuan, a 3.0% increase year-on-year, but the gross margin fell by 10.6 percentage points to 31.7%. The segment is expected to benefit from long-term trends such as aging population and improved healthcare systems [1]. Financial Forecast and Investment Recommendations - The company is projected to achieve revenues of 3.282 billion yuan, 3.896 billion yuan, and 4.721 billion yuan for 2024, 2025, and 2026 respectively, with net profits of 328 million yuan, 447 million yuan, and 578 million yuan [2][7]. - The company is recognized as a leader in the ultra-clean metal materials processing sector and is accelerating the development of high-end new products, which are expected to contribute to future growth [1].

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage [1][3]. Core Views - The company has shown significant revenue growth in the semiconductor sector, with a year-on-year increase of 48.01% in the first half of 2024, driven by a recovery in semiconductor industry demand [2][3]. - The company is one of the few domestic manufacturers capable of covering three major application areas: semiconductor, biopharmaceutical, and food and beverage, indicating strong future growth potential [3][5]. Summary by Sections Financial Performance - In the first half of 2024, the company achieved operating revenue of 1.418 billion yuan, a year-on-year increase of 11.83%, and a net profit attributable to shareholders of 140 million yuan, up 26.91% [2][3]. - The company's gross margin for H1 2024 was 25.57%, an increase of 0.75 percentage points year-on-year, while the net profit margin rose to 9.89%, up 1.18 percentage points [3][5]. Business Segments - The food segment generated revenue of 803 million yuan, a slight increase of 0.07% year-on-year, while the pharmaceutical segment saw revenue of 169 million yuan, up 2.76% [3]. - The semiconductor segment's revenue reached 447 million yuan, reflecting a robust growth of 48.01% due to improving order conditions in the semiconductor industry [3]. Future Projections - The company is projected to achieve operating revenues of 3.211 billion yuan, 3.892 billion yuan, and 4.703 billion yuan for the years 2024, 2025, and 2026, respectively [5]. - Net profit attributable to shareholders is expected to reach 326 million yuan, 448 million yuan, and 594 million yuan over the same period, indicating a strong growth trajectory [5].

Business Overview and Performance - Neway Materials' main business includes the R&D, production, and sales of clean application materials and high-purity/ultra-high-purity application materials, primarily used in food safety, biopharmaceuticals, and semiconductor industries [4] - In 2024 H1, the company achieved revenue of 1.418 billion yuan, a year-on-year increase of 11.83%, and net profit of 140 million yuan, a year-on-year increase of 26.91% [4] - The company's subsidiary, Shandong Bihai, specializes in aseptic packaging materials and liquid food filling machinery, serving clients like Yili, Nestlé, and Wahaha [8] Semiconductor Industry - The semiconductor business saw significant growth in 2024 H1 due to market recovery, with orders improving steadily [4] - The company's semiconductor products account for 3%-5% of total chip factory investment and 5%-10% of semiconductor equipment manufacturers' raw material procurement [8] - The company's "AdvanTorr" and "Nanopure" product lines are widely recognized in the semiconductor industry for their high vacuum and ultra-high purity applications [6][7] - The company is focusing on domestic substitution in the semiconductor sector, aiming for high-speed growth in equipment and facility components [9] Food Industry - Despite reduced demand in the food industry, the company maintained market share domestically, with performance remaining stable [4] - The company's aseptic packaging and filling machinery business is expanding, with plans to increase production capacity to meet growing demand [8][9] - The company is targeting domestic first-tier brands and promoting new high-speed machinery products to enhance market share [8] Future Strategy - The company will continue to focus on domestic substitution, particularly in the semiconductor and food safety sectors [9] - In the biopharmaceutical field, the company plans to increase R&D investment in high-value-added pharmaceutical-grade pumps and valves to mitigate market risks [9] - The company aims to strengthen its "equipment + packaging materials" business model in the food safety sector to increase customer loyalty and market share [9]

Investment Rating - The report maintains an "Accumulate" rating for the company [1][15]. Core Views - The company has shown steady growth in performance, with significant expansion in the semiconductor business, achieving a revenue of 1.418 billion yuan in the first half of 2024, a year-on-year increase of 11.83%. The semiconductor segment generated 447 million yuan, up 48% year-on-year, accounting for 32% of total revenue [2][9]. - The company's profit structure is improving, with a gross margin of 25.57% in the first half of 2024, an increase of 0.74 percentage points year-on-year. The net profit margin also improved to 9.89%, up 1.18 percentage points year-on-year [10][14]. - The company is focusing on domestic substitution strategies across its three main segments: semiconductor, food, and pharmaceuticals, which are expected to drive growth as downstream demand recovers [3][14]. Summary by Sections Financial Performance - In H1 2024, the company achieved total revenue of 1.418 billion yuan, with a net profit of 140 million yuan, reflecting a year-on-year increase of 26.91% [2][9]. - The second quarter revenue was 729 million yuan, up 15.88% year-on-year, with a net profit of 72 million yuan, also showing a year-on-year increase of 26.49% [2][9]. Profitability Metrics - The gross margin for H1 2024 was 25.57%, with the semiconductor segment at 28.34%, the food segment at 22.74%, and the pharmaceutical segment at 31.67% [10][14]. - The company’s net profit margin for H1 2024 was 9.89%, with a slight increase in the expense ratio to 14.73% [10][14]. Market Outlook - The global semiconductor market is expected to recover, with projected sales growth of 11.6% to 18.3% from Q4 2023 to Q2 2024. The domestic semiconductor equipment market is also showing significant growth, with sales expected to increase by 90.8% to 113.4% [3][14]. - The food packaging market in China is projected to exceed 25 billion yuan by 2025, indicating substantial growth potential, particularly in dairy and beverage sectors [3][14]. Earnings Forecast - The company’s net profit forecasts for 2024, 2025, and 2026 are 370 million yuan, 520 million yuan, and 660 million yuan, respectively, with corresponding P/E ratios of 19, 13, and 10 [15].

2024年08月26日 来源：公司年报、国金证券研究所 新莱应材 (300260.SZ) 买入(维持评级) 公司点评 证券研究报告 食品和医药业务同比持平， 半导体零组件业务保持增长 业绩简评 2024年8月26日公司披露 2024年半年报,1H24公司实现营收 14.18 亿元,同比+11.83%;实现归母净利润 1.40 亿元,同比 +26.91%,实现扣非后的归母净利润 1.32 亿元,同比+22.38%。 2Q24 单季度公司实现营收 7.29 亿元,同比+15.88%; 2Q24 实现 归母净利润 0.72 亿元,同比+26.49%,环比+5.08%;2Q24 实现 扣非后的归母净利润7249.96万元,同比+27.69%,环比+21.58%。 经营分析 综合毛利率维持稳定，2Q24 营业收入和扣非归母净利润环比改 善。1H24 综合毛利率为 25.57%, 2Q24 单季度毛利率为 25.80%, 环比提升 0.048 pcts。期间费用方面,1H24 公司期间费用率较 2023 年略有下降,为 14.73%,其中销售费用率和管理费用率基 本稳定,研发费用率为 3.54%,较 23 年底下降了 0 ...